Sami Ullah KR, Xiong YL, Miao YL, Ummair S, Dai W. Thalidomide and thalidomide analogues in treatment of patients with inflammatory bowel disease: Meta-analysis. World J Meta-Anal 2017; 5(5): 124-131 [DOI: 10.13105/wjma.v5.i5.124]
Corresponding Author of This Article
Dr. Wei Dai, Department of Gastroenterology, First Affiliated Hospital of Kunming Medical University, Yunnan Institute of Digestive Disease, 295 Xichang Road, Kunming 650032, Yunnan Province, China. myldu@sina.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Meta-Anal. Oct 26, 2017; 5(5): 124-131 Published online Oct 26, 2017. doi: 10.13105/wjma.v5.i5.124
Thalidomide and thalidomide analogues in treatment of patients with inflammatory bowel disease: Meta-analysis
Khan Rana Sami Ullah, Yu-Lin Xiong, Ying-Lei Miao, Saeed Ummair, Wei Dai
Khan Rana Sami Ullah, Ying-Lei Miao, Wei Dai, Department of Gastroenterology, First Affiliated Hospital of Kunming Medical University, Yunnan Institute of Digestive Disease, Kunming 650032, Yunnan Province, China
Yu-Lin Xiong, Library of Kunming Medical University, Kunming 650032, Yunnan Province, China
Saeed Ummair, Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China
Author contributions: Sami Ullah KR and Xiong YL contributed equally to this study; Miao YL and Dai W supervised this study; Ummair S also contributed in this study.
Conflict-of-interest statement: The authors assured no confliction of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Wei Dai, Department of Gastroenterology, First Affiliated Hospital of Kunming Medical University, Yunnan Institute of Digestive Disease, 295 Xichang Road, Kunming 650032, Yunnan Province, China. myldu@sina.com
Telephone: +86-871-65324888
Received: January 21, 2017 Peer-review started: January 22, 2017 First decision: March 8, 2017 Revised: May 5, 2017 Accepted: June 30, 2017 Article in press: July 1, 2017 Published online: October 26, 2017 Processing time: 276 Days and 10 Hours
Core Tip
Core tip: The aim of this meta-analysis is to examine the efficacy and safety of thalidomide and thalidomide analogues for induction and maintenance of remission in patients with inflammatory bowel disease (IBD). The literature was searched in the databases: PubMed, EMBASE, Ovid and the Cochrane Library, and Chinese databases. The Randomized Controlled Trials was performed during this analysis to assess the effects of thalidomide therapy on IBD patients that did show good response with other therapies. Weighted pooled outcomes were synthesized with a fixed-effects model to account for clinical heterogeneity. This meta-analysis showed that there is not enough evidence to support the use of thalidomide or its analogues in the treatment of IBD for patients of any age.
